Major Milestone: Affinity’s Legubicin for Injection Granted FDA Orphan Drug Designation, Ushering in a New Chapter for Soft Tissue Sarcoma Treatment

Affinity Presents Breakthrough Preclinical Data of First-in-Class Dual-Masked CLDN6-CD3 TMEA-TCE at AACR: Potent Anti-Tumor Activity with No Observed CRS Signals

Affinity Presents First-in-Class TME-Activated IL-2 Platform (TMEABody) and Clinical Data at AACR, Addressing the Toxicity Challenge of Traditional IL-2 Therapies

Affinity Unveils World’s First Dual-Payload ADC Breakthrough Offering Novel Solutions for RAS-Mutant Tumors and ADC Resistance